8 Australian biotech companies — 5 of them formed with Proto Axiom as founding investor. Sourced from 6 universities and the public health system. 4 are approaching clinical trials.
A first‑in‑class oral insulin platform using liver‑targeting nanotechnology, addressing a multi‑billion‑dollar diabetes market with no currently approved oral product.
“Insulin in a pill, ten years from bench to first-in-human.”
A deep‑tech genomics company developing a next‑generation DNA sequencing platform based on plasmonic nanoantenna technology — true single‑molecule sequencing without the traditional trade‑offs between accuracy, read length, cost and speed.
“A new way to read the molecule. Built in Sydney.”
A next‑generation topical antifungal for onychomycosis — combining the safety of topical therapy with efficacy approaching oral drugs, via a novel lyotropic liquid crystal drug‑delivery system.
“Phase IIb under way. Topical efficacy, oral-grade results.”
A platform biotechnology company developing NAD+ technologies to modulate cellular energy, metabolism and ageing biology — with IVF laboratory media as the lead clinical and commercial application.
“Better embryos, by way of cellular energy.”
A bioprocessing technology company developing novel downstream purification materials and workflows that improve the efficiency, cost and scalability of biologics manufacturing.
“A bottleneck in biologics, addressed onshore.”
Clinical‑stage radiopharmaceutical company developing targeted alpha therapies using lead‑212 (²¹²Pb) for cancers with poor existing standards of care.
“80% PSA50 response. ESMO 2025.”
A desktop RNA printer enabling rapid, distributed production of RNA for research and rare‑disease therapeutic applications.
“RNA, on demand, at the bench.”
A novel biomanufacturing platform — initially focused on human‑health compounds, now leading with an AI soil‑microbe product to reduce reliance on imported fertilisers.
“Sovereign fertiliser, made by microbes.”
University of Sydney, UNSW Sydney, Monash University, Griffith University, ANZAC Research Institute, Sydney Local Health District.
Researcher with a translational program?
Apply to Challenger Summit →